Pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic biomarkers for neuroblastoma risk stratification - Top-Institutions - MDSpire

Pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic biomarkers for neuroblastoma risk stratification

  • By

  • Lixiao Shi

  • Dixiao Zhong

  • Ruihong Tang

  • Duanfang Shao

  • Xiang Cheng

  • Zhaoxia Zhang

  • Rong Liu

  • June 15, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Capital Center for Children’s Health
    Capital Center for Children’s Health

    Washington, DC

    Key Differentiators

    • Pediatric Oncology

  • #2

    Capital Medical University
    Capital Medical University

    Beijing, Beijing

    Key Differentiators

    • Medical Education
    • Oncology

  • #3

    Center A
    Center A

    Unknown, Unknown

    Key Differentiators

    • Oncology

  • #4

    Center B
    Center B

    Unknown, Unknown

    Key Differentiators

    • Oncology

  • #5

    Center C
    Center C

    Unknown, Unknown

    Key Differentiators

    • Oncology

Original Source(s)

Pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic biomarkers for neuroblastoma risk stratification

  • by Lixiao Shi, Dixiao Zhong, Ruihong Tang, Duanfang Shao, Xiang Cheng, Zhaoxia Zhang, Rong Liu

  • June 15, 2026

Related Content

HOX gene dysregulation in head and neck squamous cell carcinoma: mechanisms, clinical relevance, and future perspectives

Who Decides How AI Enters Pathology?

Liron Pantanowitz explains why validation, leadership, and real-world use matter more than performance metrics

Intracranial angiomatoid fibrous histiocytoma in a 2-month-old infant: a rare case report